Editorial
Atherogenic dyslipidaemia: the other pandemic, associated with diabesity
Dislipemia aterogénica: la otra pandemia, asociada a la diabesidad
Read
484
Timeswas read the article
139
Total PDF
345
Total HTML
Share statistics
array:23 [ "pii" => "S2529912321000097" "issn" => "25299123" "doi" => "10.1016/j.artere.2021.01.002" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "560" "copyrightAnyo" => "2021" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Investig Arterioscler. 2021;33:30-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:18 [ "pii" => "S0214916820301297" "issn" => "02149168" "doi" => "10.1016/j.arteri.2020.12.001" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "560" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Invest Arterioscl. 2021;33:30-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Dislipemia aterogénica: la otra pandemia, asociada a la diabesidad" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "30" "paginaFinal" => "32" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Atherogenic dyslipemia: the other pandemic, associated with diabesity" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jesús Millán Núñez-Cortés, Juan Pedro-Botet" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jesús Millán" "apellidos" => "Núñez-Cortés" ] 1 => array:2 [ "nombre" => "Juan" "apellidos" => "Pedro-Botet" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529912321000097" "doi" => "10.1016/j.artere.2021.01.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912321000097?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916820301297?idApp=UINPBA00004N" "url" => "/02149168/0000003300000001/v1_202101150633/S0214916820301297/v1_202101150633/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2529912320300887" "issn" => "25299123" "doi" => "10.1016/j.artere.2020.12.004" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "544" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Clin Investig Arterioscler. 2021;33:33-40" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "33" "paginaFinal" => "40" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares?" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1511 "Ancho" => 2508 "Tamanyo" => 251317 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Empaglyphlozin induces a more energy-efficient change in the metabolic substrate at the myocardial level ATP: adenosine triphosphate; BCAA: branched- chain amino acids; FFA: unesterified free fatty acids; Glc: glucose.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ariana P. Vargas Delgado, Juan Antonio Requena Ibañez, Carlos G. Santos-Gallego, Juan Jose Badimon" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Ariana P." "apellidos" => "Vargas Delgado" ] 1 => array:2 [ "nombre" => "Juan Antonio" "apellidos" => "Requena Ibañez" ] 2 => array:2 [ "nombre" => "Carlos G." "apellidos" => "Santos-Gallego" ] 3 => array:2 [ "nombre" => "Juan Jose" "apellidos" => "Badimon" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0214916820300838" "doi" => "10.1016/j.arteri.2020.08.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916820300838?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300887?idApp=UINPBA00004N" "url" => "/25299123/0000003300000001/v2_202102250929/S2529912320300887/v2_202102250929/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2529912320300875" "issn" => "25299123" "doi" => "10.1016/j.artere.2020.12.003" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "5431" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Clin Investig Arterioscler. 2021;33:19-29" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Related cardiometabolic factors and prevalence of low HDL-cholesterol levels and atherogenic dyslipidemia. SIMETAP-AD study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "19" "paginaFinal" => "29" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Factores cardiometabólicos asociados y prevalencia de concentraciones bajas de colesterol HDL y de dislipidemia aterogénica. Estudio SIMETAP-DA" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1072 "Ancho" => 2128 "Tamanyo" => 208855 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Prevalence of low HDL-C according to age and sex.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">M: males; F: females; n: number of cases; N: sample size; p: p-value of the difference (M-F).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Antonio Ruiz-García, Ezequiel Arranz-Martínez, María E. García-Fernández, Roberto Cabrera-Vélez, Rosa A. García-Pliego, Luis E. Morales-Cobos, Blanca Sanz-Pozo, Esther Gómez-Díaz, Enrique Rodríguez-de-Mingo, María R. Rico-Pérez, Alfonso Migueláñez-Valero, María P. Calderín-Morales, Eloína Sandín-de-Vega, María P. Hombrados-Gonzalo, Sonia Luna-Ramírez, María C. Sánchez-Ramos, Cristina Mora-Casado, María S. Moreno-Muñoz, Paloma González-Escobar, Lourdes Ruiz-Díaz, Nuria Caballero-Ramírez, María M. Zamora-Gómez, Nerea Iturmendi-Martínez, María S. Holgado-Catalán, Rebeca Álvarez-Benedicto, Pedro L. Sanchidriá-Fernández, Elena Benito-Alonso, Teresa Fernández-Vicente, Rosa M. Hernández-López, Norma A. Doria-Carlin, Manuel J. Frías-Vargas" "autores" => array:32 [ 0 => array:2 [ "nombre" => "Antonio" "apellidos" => "Ruiz-García" ] 1 => array:2 [ "nombre" => "Ezequiel" "apellidos" => "Arranz-Martínez" ] 2 => array:2 [ "nombre" => "María E." "apellidos" => "García-Fernández" ] 3 => array:2 [ "nombre" => "Roberto" "apellidos" => "Cabrera-Vélez" ] 4 => array:2 [ "nombre" => "Rosa A." "apellidos" => "García-Pliego" ] 5 => array:2 [ "nombre" => "Luis E." "apellidos" => "Morales-Cobos" ] 6 => array:2 [ "nombre" => "Blanca" "apellidos" => "Sanz-Pozo" ] 7 => array:2 [ "nombre" => "Esther" "apellidos" => "Gómez-Díaz" ] 8 => array:2 [ "nombre" => "Enrique" "apellidos" => "Rodríguez-de-Mingo" ] 9 => array:2 [ "nombre" => "María R." "apellidos" => "Rico-Pérez" ] 10 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Migueláñez-Valero" ] 11 => array:2 [ "nombre" => "María P." "apellidos" => "Calderín-Morales" ] 12 => array:2 [ "nombre" => "Eloína" "apellidos" => "Sandín-de-Vega" ] 13 => array:2 [ "nombre" => "María P." "apellidos" => "Hombrados-Gonzalo" ] 14 => array:2 [ "nombre" => "Sonia" "apellidos" => "Luna-Ramírez" ] 15 => array:2 [ "nombre" => "María C." "apellidos" => "Sánchez-Ramos" ] 16 => array:2 [ "nombre" => "Cristina" "apellidos" => "Mora-Casado" ] 17 => array:2 [ "nombre" => "María S." "apellidos" => "Moreno-Muñoz" ] 18 => array:2 [ "nombre" => "Paloma" "apellidos" => "González-Escobar" ] 19 => array:2 [ "nombre" => "Lourdes" "apellidos" => "Ruiz-Díaz" ] 20 => array:2 [ "nombre" => "Nuria" "apellidos" => "Caballero-Ramírez" ] 21 => array:2 [ "nombre" => "María M." "apellidos" => "Zamora-Gómez" ] 22 => array:2 [ "nombre" => "Nerea" "apellidos" => "Iturmendi-Martínez" ] 23 => array:2 [ "nombre" => "María S." "apellidos" => "Holgado-Catalán" ] 24 => array:2 [ "nombre" => "Rebeca" "apellidos" => "Álvarez-Benedicto" ] 25 => array:2 [ "nombre" => "Pedro L." "apellidos" => "Sanchidriá-Fernández" ] 26 => array:2 [ "nombre" => "Elena" "apellidos" => "Benito-Alonso" ] 27 => array:2 [ "nombre" => "Teresa" "apellidos" => "Fernández-Vicente" ] 28 => array:2 [ "nombre" => "Rosa M." "apellidos" => "Hernández-López" ] 29 => array:2 [ "nombre" => "Norma A." "apellidos" => "Doria-Carlin" ] 30 => array:2 [ "nombre" => "Manuel J." "apellidos" => "Frías-Vargas" ] 31 => array:1 [ "colaborador" => "on behalf of the SIMETAP Study Research Group" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0214916820300668" "doi" => "10.1016/j.arteri.2020.06.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916820300668?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912320300875?idApp=UINPBA00004N" "url" => "/25299123/0000003300000001/v2_202102250929/S2529912320300875/v2_202102250929/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Atherogenic dyslipidaemia: the other pandemic, associated with diabesity" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "30" "paginaFinal" => "32" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jesús Millán Núñez-Cortés, Juan Pedro-Botet" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Jesús Millán" "apellidos" => "Núñez-Cortés" "email" => array:1 [ 0 => "jesus.millan.nunezcortes@madrid.org" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Juan" "apellidos" => "Pedro-Botet" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Lipids Unit, General University Hospital Gregorio Marañón, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Atherogenic Dyslipidaemia Work Group, Spanish Artherosclerosis Society, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Lipis and Vascular Risk Unit, Hospital del Mar, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Dislipemia aterogénica: la otra pandemia, asociada a la diabesidad" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">When medicine successfully combats the current COVID-19 pandemic caused by coronavirus SARS-CoV-2, we will still face the challenge of another pandemic, that has already been around for many years and which, rather than disappearing, has been increasing its impact year after year. In this sense, a great deal of cardiovascular morbimortality is associated with high cardiovascular risk which is characteristic of certain cardiometabolic disorders. Diabetes mellitus type 2 and obesity are paradigmatic elements of this and at the same time are frequently found encompassed in what is recognised from a clinical and physiopathological viewpoint as metabolic syndrome.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In the study by Ruiz-García and cols. published in this edition of <span class="elsevierStyleItalic">Clin Invest Arterioscl</span>,<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> the SIMETAP study group presents the prevalence of characteristic changes of artherogenic dyslipidaemia in population analysis in primary care. The results leave no room for doubt. In this study the factors most significantly associated with atherogenic dyslipidaemia, or one of its constitutive elements such as low HDLc, are obesity and/or diabetes, together with a tobacco habit. Furthermore, it highlights the association of hypertriglyceridaemia in this population with low rates of HDLc. This study is therefore a wake-up call for the critical need for a diagnostic and therapeutic proposal to detect and treat, respectively, atherogenic dyslipidaemia and especially in patients with disorders known as cardiometabolic.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The Atherogenic dyslipidaemia workgroup of the Spanish Arthrosclerosis Society has recently made public the prevalence of this specific dyslipidaemia in diabetics (PREDISAT study). Up to 41% of diabetic patients have atherogenic dyslipidaemia<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> with mean aglyceridemia close to 500 mg/dL and HDLc of 33 mg/dL. Therapeutic intervention appears to be largely inadequate because, in the majority of case statins are the most widely used treatment whilst more appropriate hypotriglyceridemiants are not used. Following pharmacological treatment 35% of the diabetic population still continue having atherogenic dyslipidaemia. Moreover, a lower proportion of older patients receive treatment and the problem is therefore clearly undertreated and undercontrolled.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> However, in diabetic patients in secondary prevention, the prevalence is greater still (51%), regardless of the fact this is a coronary cardiac, cerebrovascular or peripheral arterial disease.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">It is precisely the high prevalence of atherogenic dyslipidaemia in patients with high or very high risk treated with statins, that has led to the consideration of risk attributable to this disorder, even considering a conventional treatment with hypocholesterolemiants, regardless of having target LDLc levels. This is the origin of the concept of residual risk of lipid origin: the persistence of an elevated cardiovascular risk despite standard and acceptable control of LDLc. Residual risk is again endorsed by the Ruiz-García and cols. Study.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> This is a concept which, despite everything, is found to be evolving because the building blocks of a residual risk fraction are increasingly described and they do not only focus on lipoproteins rich in triglycerides, as in the case of lipoprotein (a) [Lp(a)]; or they are not strictly lipid, as in the case of the inflammatory phenomena or the prothrombotic agents that accompany metabolic syndrome, diabetes mellitus or visceral obesity.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> It is precisely in diabetic patients where inflammation may be a major contributing factor to residual cardiovascular risk, particularly in those with nephropathy; although they are also very directly related with obesity or the elevation of the c-no-HDL.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The concentration of triglycerides and HDLc allows us to identify people with atherogenic dyslipidaemia and with high cardiovascular risk. In fact, the number of triglycerides is a surrogate marker of lipoproteins rich in triglycerides and their remnants.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> And, as is known, the remaining lipoproteins contribute unequivocally to increasing the risk of lipid origin. In recent results from the cohort of the Copenhagen study it was confirmed that the risk of severe coronary accident recurrence in patients with myocardial infarction or previous stroke is directly related to the rate of cholesterol linked to remaining lipoproteins: +23% with figures of 19−38 mg/dL, +48% with 39−57 mg/dL, and +79% with figures higher than 58 mg/dL.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> Moreover, in people who are overweight or obese with high cardiovascular risk, the levels of triglycerides and remnant cholesterol but not LDLc, are associated with the cardiovascular objectives regardless of other risk factors.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Remnant lipoproteins are derive d by lipolysis from VLDL (which contain apoB) and from chyomicrons (which contain apoB48), and their composition and size varies when they are enriched with cholesterol and apoE esters.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> The quantitative determination of remnant lipoproteins lacks standardisation in its measuring technique, but may be essential for explaining the causes of residual risk of lipid origin. This is especially the case if it is related to another component of atherogenic dyslipidaemia, such as the already quoted drop in HDLc. Recently in a population of approximately 1,500 individuals, with a 25-year follow-up it was reported that the triglyceride/HDLc index is a good predictor regardless of the appearance of diabetes mellitus,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> and this elevates this parameter to the category of a general population predictor.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The need for suitable control of these patients must be insisted upon. In the NHANES study, approximately 25% of the patients treated with statins presented with a concentration of triglycerides above 150 mg/dL.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Therefore, despite the fact that in the guidelines it is generally recommended that a statin be the first line treatment, this may be insufficient for a considerable percentage of cases, which require a complementary therapeutic strategy due to the need to reduce the residual risk from hyperglyceridaemia. First in ranking of options are the fibrates. In the ACCORDION study, the patients with the highest triglyceride levels and lowest HDLc levels had better long-term outcomes when they were treated with a combination of statins with fenofibrate rather than only statins. There was a lower incidence of cardiovascular mortality, of non fatal myocardial infarction, heart failure or severe coronary episodes; and together with this there was a significant reduction in mortality from all causes (-35%) after almost 5 years of follow-up.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> These data present an opportunity for more selective PPAR-α modulators, such as the pemafibrate<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> or dual drugs which combine an apoCII mimetic with a apoCIII antagonist.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">The treatment of elevate rates of LDLc is a “first line” treatment objective and cornerstone of cardiovascular prevention. However, this lipid fraction does not faithfully reflect the underlying lipid disorder in a high percentage of patients with elevation of lipoproteins rich in triglycerides (intermediate density VLDL, remnants). This is pointing us in the correct and complementary direction of good LDLc control: (a) a better knowledge of current management in the diagnosis of this lipoprotein alteration intended to introduces the necessary changes to clinical practice, and (b) greater knowledge which may lead to clarifying therapeutic aspects such as the non-HDLc as therapeutic target, more effective and safer intervention strategies against overall dyslipidaemia (for example, drug combinations), or clinical outcomes which include those that lead to the evaluation of atheromatous plaque evolution.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Núñez-Cortés JM. Dislipemia aterogénica: la otra pandemia, asociada a la diabesidad. Clin Investig Arterioscler. 2020. <span class="elsevierStyleInterRef" id="intr0005" href="https://doi.org/10.1016/j.arteri.2020.12.001">https://doi.org/10.1016/j.arteri.2020.12.001</span></p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COSMIC project: consensus on the objectives of the metabolic syndrome in clinic" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Pedro-Botet" 1 => "J.F. Ascaso" 2 => "V. Barrios" 3 => "A. De la Sierra" 4 => "J. Escalada" 5 => "J. Millán" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/DMSO.S165740" "Revista" => array:6 [ "tituloSerie" => "Diabetes Metab Syndr Obes." "fecha" => "2018" "volumen" => "11" "paginaInicial" => "683" "paginaFinal" => "697" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30464566" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Factores cardiometabólicos asociados y prevalencia de concentraciones bajas de colesterol HDL y de dislipemia aterogénica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Ruiz-Garcia" 1 => "E. Arranz-Martinez" 2 => "M.E. Garcia Fernandez" 3 => "R. Cabrera-Velez" 4 => "R.A. Garcia-Pliego" 5 => "L.E. Morales-Cobos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Estudio SIMETAL-DA. Clin Invest Arterioscl" "fecha" => "2020" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Millan J., Ascaso J., Blasco M., Brea A., Diaz A., Hernandez Mijares A., et al. Atherogenic dyslipidaemia in diabetics: overall results of the PREDISAT study. 88th EAS Congress. 04-07 October, 2020." ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ascaso J.F., Hernandez Mijares A., Blasco M., Brea A., Diaz A., Pedro-Botet J., et al. PREDISAT study in Spain: age and gender factors associated with atherogenic dyslipidaemia prevalence in diabetics. 88th EAS Congress. 04-07 October, 2020." ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "- Pedro-Botet J, Pintó X, Ascaso J, Blasco M, Brea A, Diaz A., et al. High prevalence of atherogenic dyslipidaemia in diabetics with conditioning factors for high cardiovascular risk. 88th EAS Congress. 04-07, 2020." ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The evolving understanding and approach to residual cardiovascular risk management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.A. Dhindsa" 1 => "P.B. Sandesara" 2 => "M.D. Shapiro" 3 => "N.D. Wong" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Front Cardiovasc Med" "fecha" => "2020" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Prattichizzo" 1 => "A. Giuliani" 2 => "J. Sabbatinelli" 3 => "G. Matacchione" 4 => "D. Ramini" 5 => "A.R. Bonfigli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/dom.14081" "Revista" => array:6 [ "tituloSerie" => "Diabetes Obes Metab." "fecha" => "2020" "volumen" => "22" "paginaInicial" => "1696" "paginaFinal" => "1700" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32394604" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Triglycerides and residual risk" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.J. Vallejo-Vaz" 1 => "P. Corral" 2 => "L. Schreier" 3 => "K.K. Ray" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Curr Opin Endocrinol Diabetes Obes." "fecha" => "2020" "volumen" => "27" "paginaInicial" => "91" "paginaFinal" => "103" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Contribution of remnant cholesterol to cardiovascular risk" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Langsted" 1 => "C.M. Madsen" 2 => "B.G. Nordestgaard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/joim.13059" "Revista" => array:6 [ "tituloSerie" => "J Intern Med." "fecha" => "2020" "volumen" => "288" "paginaInicial" => "116" "paginaFinal" => "127" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32181933" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Castañer" 1 => "X. Pintó" 2 => "I. Subirana" 3 => "A.J. Amor" 4 => "E. Ros" 5 => "Á Hernáez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2020.10.008" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol." "fecha" => "2020" "volumen" => "76" "paginaInicial" => "2712" "paginaFinal" => "2724" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33272365" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Remnants of the triglyceride-rich lipoproteins, diabetes and cardiovascular disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Chait" 1 => "H.N. Ginsberg" 2 => "T. Vaisar" 3 => "J.W. Heinecke" 4 => "I.J. Goldberg" 5 => "K.E. Bornfeldt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dbi19-0007" "Revista" => array:6 [ "tituloSerie" => "Diabetes." "fecha" => "2020" "volumen" => "69" "paginaInicial" => "508" "paginaFinal" => "516" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32198194" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of US adults with triglycerides ≥150 mg/dL: NHANES 2007-2014" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "W. Fan" 1 => "S. Philip" 2 => "C. Granowitz" 3 => "P.P. Toth" 4 => "N.D. Wong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40119-020-00170-x" "Revista" => array:6 [ "tituloSerie" => "Cardiol Ther." "fecha" => "2020" "volumen" => "9" "paginaInicial" => "207" "paginaFinal" => "213" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32328971" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidaemia: a secondary analysis of the ACCORDION study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Zhu" 1 => "A. Hayen" 2 => "K.J.L. Bell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12933-020-01002-x" "Revista" => array:5 [ "tituloSerie" => "Cardiovasc Diabetol." "fecha" => "2020" "volumen" => "19" "paginaInicial" => "28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32138746" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemis and metabolic diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Yamashita" 1 => "D. Masuda" 2 => "Y. Matsuzawa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11883-020-0823-5" "Revista" => array:5 [ "tituloSerie" => "Curr Atheroscler Rep." "fecha" => "2020" "volumen" => "22" "paginaInicial" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31974794" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Wolska" 1 => "L. Lo" 2 => "D.O. Sviridov" 3 => "M. Pourmousa" 4 => "M. Pryor" 5 => "S.S. Ghosh" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Sci Transl Med" "fecha" => "2020" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25299123/0000003300000001/v2_202102250929/S2529912321000097/v2_202102250929/en/main.assets" "Apartado" => array:4 [ "identificador" => "63723" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003300000001/v2_202102250929/S2529912321000097/v2_202102250929/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912321000097?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 2 | 1 | 3 |
| 2024 October | 6 | 2 | 8 |
| 2024 September | 26 | 3 | 29 |
| 2024 August | 24 | 3 | 27 |
| 2024 July | 13 | 4 | 17 |
| 2024 June | 6 | 6 | 12 |
| 2024 May | 8 | 2 | 10 |
| 2024 April | 8 | 2 | 10 |
| 2024 March | 13 | 4 | 17 |
| 2024 February | 8 | 2 | 10 |
| 2024 January | 31 | 1 | 32 |
| 2023 December | 7 | 3 | 10 |
| 2023 November | 11 | 4 | 15 |
| 2023 October | 8 | 5 | 13 |
| 2023 September | 8 | 4 | 12 |
| 2023 August | 8 | 3 | 11 |
| 2023 July | 6 | 6 | 12 |
| 2023 June | 8 | 7 | 15 |
| 2023 May | 6 | 4 | 10 |
| 2023 April | 8 | 4 | 12 |
| 2023 March | 12 | 3 | 15 |
| 2023 February | 11 | 3 | 14 |
| 2023 January | 9 | 5 | 14 |
| 2022 December | 11 | 5 | 16 |
| 2022 November | 8 | 6 | 14 |
| 2022 October | 10 | 5 | 15 |
| 2022 September | 16 | 3 | 19 |
| 2022 August | 11 | 6 | 17 |
| 2022 July | 7 | 8 | 15 |
| 2022 June | 7 | 4 | 11 |
| 2022 May | 8 | 8 | 16 |
| 2022 April | 7 | 4 | 11 |
| 2022 March | 6 | 5 | 11 |
| 2022 February | 7 | 4 | 11 |
Show all